MBC 115

Known as: MBC-115 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2018
012320082018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND This study described real-world palbociclib dosing patterns and associated impacts on treatment costs for HR+/HER2… (More)
Is this relevant?
2017
2017
HR+ MBC after progression on an nsAI [10]. In this study, similar to PALOMA-3 and MONARCH-2 trials, patients with prior exposure… (More)
Is this relevant?
2016
2016
Medullary breast cancer (MBC) is a rare tumor associated with a better prognosis compared with other breast cancers. The role of… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Review
2016
Review
2016
Prior to availability of anti-HER2 therapies, HER2-positive metastatic breast cancer (MBC) was associated with a poor prognosis… (More)
  • figure 1
  • table 1
Is this relevant?
2013
2013
Epidermal growth factor (EGF) is a ligand for the epidermal growth factor receptor (EGFR). Human epidermal growth factor receptor… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2013
2013
To evaluate the relationship between IL-11 and bone metastasis in patients with breast cancer and explore the potential molecular… (More)
Is this relevant?
Review
2011
Review
2011
Trastuzumab demonstrates significant clinical benefits in HER2-positive metastatic breast cancer (MBC), and recent clinical… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2009
2009
1057 Background: Approximately 50% of HER2+ breast cancers are HR+ (defined as estrogen receptor [ER] and/or progesterone… (More)
Is this relevant?
2009
2009
1000 Background: GD and CD are efficacious in patients (pts) with MBC. This study compared safety and efficacy of GD and CD… (More)
Is this relevant?
2008
2008
BACKGROUND Gemcitabine and carboplatin have significant preclinical synergy, and both provide synergistic antitumor activity in… (More)
Is this relevant?